カテゴリ： GlobalData, アメリカ, 企業調査

Acorda Therapeutics Inc (ACOR)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Acorda Therapeutics Inc (ACOR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8014179
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：80
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Acorda Therapeutics Inc (Acorda) is a biopharmaceutical company that discovers, develops, and commercializes therapies for treating patients with neurological disorders. The company’s commercial products include Ampyra (dalfampridine), a treatment to improve walking in patients with multiple sclerosis (MS); Zanaflex Capsules and tablets, for the management of spasticity; and Qutenza, dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It is also developing a pipeline of neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine, MS, heart failure and spinal cord injury. Acorda sells its products through wholesale pharmaceutical distributors to retail pharmacies and specialty pharmacy providers. It has subsidiaries in the US and Europe. Acorda is headquartered in Ardsley, New York, the US.

Acorda Therapeutics Inc (ACOR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Acorda Therapeutics Completes Acquisition Of Rights To Qutenza And NGX-1998 From NeurogesX For US$13 Million 12
Venture Financing 14
Civitas Therapeutics Raises USD55 Million in Series C Financing 14
Civitas Therapeutics Raises US$38 Million In Series B Venture Financing 16
Civitas Therapeutics Secures US$5 Million In Venture Financing 18
Civitas Therapeutics Secures An Additional US$8 Million In Series A Financing Round 19
Partnerships 20
Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 20
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 21
Licensing Agreements 22
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 22
Acorda Therapeutics Enters Into Licensing Agreement With Medtronic For AC105 23
Equity Offering 24
Acorda Therapeutics Plans to Raise Funds through Rights Offering of Preferred Shares 24
Acorda Therapeutics Raises USD75 Million in Private Placement of Shares 25
Biotie Therapies Raises USD56.6 Million in Public Offering of ADSs 26
Civitas Therapeutics Withdraw IPO for up to USD80 million 28
Biotie Therapies Completes Private Placement Of Shares For US$25 Million 29
Biotie Therapies Completes Private Placement Of Treasury Shares For US$37.4 Million 30
Debt Offering 31
Biotie Therapies to Raise USD45.6 Million in Private Placement of Notes and Warrants 31
Acorda Therapeutics Raises USD345 Million in Public Offering of Notes Due 2021 33
Acquisition 35
Acorda Therapeutics Rejects Plan of its Sale 35
Acorda Therapeutics Acquires Biotie Therapies in Tender Offer 36
Acorda Therapeutics Acquires Civitas Therapeutics for USD525 Million 38
Acorda Therapeutics Completes Acquisition Of Neuronex For Up To US$141 Million 40
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 42
Biotie Therapies Acquires Synosia Therapeutics 43
Acorda Therapeutics Inc – Key Competitors 46
Acorda Therapeutics Inc – Key Employees 47
Acorda Therapeutics Inc – Locations And Subsidiaries 48
Head Office 48
Other Locations & Subsidiaries 48
Recent Developments 50
Strategy And Business Planning 50
Apr 05, 2017: Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs 50
Financial Announcements 51
Oct 31, 2017: Acorda Provides Financial and Pipeline Update for Third Quarter 2017 51
Jul 27, 2017: Acorda Provides Financial and Pipeline Update for Second Quarter 2017 53
Apr 27, 2017: Acorda Provides Financial and Pipeline Update for First Quarter 2017 55
Feb 14, 2017: Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016 57
Oct 27, 2016: Acorda Provides Financial and Pipeline Update for Third Quarter 2016 59
Jul 28, 2016: Acorda Provides Financial and Pipeline Update for Second Quarter 2016 61
Apr 28, 2016: Acorda Provides Financial and Pipeline Update for First Quarter 2016 63
Feb 11, 2016: Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2015 65
Corporate Communications 67
Feb 21, 2017: Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board of Directors 67
Apr 10, 2016: Acorda Announces Departure of Michael Rogers 68
Product News 69
04/05/2017: Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs 69
Product Approvals 70
Aug 26, 2016: Biotie: BTT1023 Receives Orphan Drug Designation in the United States 70
Clinical Trials 71
Jun 06, 2017: Acorda Presenting New Tozadenant Data at 2017 MDS Congress 71
Mar 29, 2017: Acorda Announces Long-Term Safety Data for CVT-301 72
Feb 09, 2017: Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-301 74
Oct 13, 2016: Data from Clinical and Preclinical Trials of CVT-301 for Treatment of OFF Periods in Parkinsons Disease Published in Science Translational Medicine 76
Apr 20, 2016: Acorda Announces Results from Phase 2b Clinical Trial of CVT-301 for Treatment of OFF Periods in Parkinson’s Disease Published in Movement Disorders 77
Apr 07, 2016: Phase 2b Data on Inhaled Levodopa CVT-301 Featured in Invited Science Session at American Academy of Neurology (AAN) Annual Meeting 79
Appendix 80
Methodology 80
About GlobalData 80
Contact Us 80
Disclaimer 80

List of Tables
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Acorda Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Acorda Therapeutics Completes Acquisition Of Rights To Qutenza And NGX-1998 From NeurogesX For US$13 Million 12
Civitas Therapeutics Raises USD55 Million in Series C Financing 14
Civitas Therapeutics Raises US$38 Million In Series B Venture Financing 16
Civitas Therapeutics Secures US$5 Million In Venture Financing 18
Civitas Therapeutics Secures An Additional US$8 Million In Series A Financing Round 19
Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 20
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 21
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 22
Acorda Therapeutics Enters Into Licensing Agreement With Medtronic For AC105 23
Acorda Therapeutics Plans to Raise Funds through Rights Offering of Preferred Shares 24
Acorda Therapeutics Raises USD75 Million in Private Placement of Shares 25
Biotie Therapies Raises USD56.6 Million in Public Offering of ADSs 26
Civitas Therapeutics Withdraw IPO for up to USD80 million 28
Biotie Therapies Completes Private Placement Of Shares For US$25 Million 29
Biotie Therapies Completes Private Placement Of Treasury Shares For US$37.4 Million 30
Biotie Therapies to Raise USD45.6 Million in Private Placement of Notes and Warrants 31
Acorda Therapeutics Raises USD345 Million in Public Offering of Notes Due 2021 33
Acorda Therapeutics Rejects Plan of its Sale 35
Acorda Therapeutics Acquires Biotie Therapies in Tender Offer 36
Acorda Therapeutics Acquires Civitas Therapeutics for USD525 Million 38
Acorda Therapeutics Completes Acquisition Of Neuronex For Up To US$141 Million 40
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 42
Biotie Therapies Acquires Synosia Therapeutics 43
Acorda Therapeutics Inc, Key Competitors 46
Acorda Therapeutics Inc, Key Employees 47
Acorda Therapeutics Inc, Subsidiaries 48

★海外企業調査レポート[Acorda Therapeutics Inc (ACOR)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • WAVE Life Sciences Ltd (WVE)：企業の財務・戦略的SWOT分析
    Summary Wave Life Sciences Ltd (Wave Life Sciences) formerly WAVE Life Sciences Pte Ltd, discovers, develops and commercializes medicines for genetic diseases. The company's pipeline comprises an mRNA transcript candidates: WVE-120101 and WVE-120102 for Huntington's disease; ATXN3 gene candidate for …
  • Aeon Co., Ltd.：企業の戦略・SWOT・財務情報
    Aeon Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Aeon Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Huhtamaki Oyj：企業のM&A・事業提携・投資動向
    Huhtamaki Oyj - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Huhtamaki Oyj Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • ULURU Inc (ULUR)-医療機器分野：企業M&A・提携分析
    Summary ULURU Inc (ULURU) is a developer and commercializer of wound care and muco-adhesive film products. The company’s products include Altrazeal and OraDisc. Its Altrazeal is a transforming powder dressing with Nanoflex technology for the management of exuding wounds. ULURU’s OraDisc is a polymer …
  • Xspray Pharma AB (XSPRAY)：製薬・医療：M&Aディール及び事業提携情報
    Summary Xspray Pharma AB (Xspray Pharma), formerly Xspray Microparticles AB, is a drug development company that develops and commercializes protein kinase inhibitors (PKI) for targeted cancer treatments. The company’s drug candidates include HyNap-Dasa, HyNap-Nilo and HyNap-Sora. Its protein kinase …
  • Luna Innovations Inc (LUNA)：医療機器：M&Aディール及び事業提携情報
    Summary Luna Innovations Inc (Luna) is an optical technology development company that research, develops and commercializes speed optics and fiber optic test products. The company provides products such as fiber optic sensing products, fiber optic test and measurement products, high speed optical pr …
  • Hino Motors Ltd (7205)：企業の財務・戦略的SWOT分析
    Hino Motors Ltd (7205) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Kewpie Corporation：戦略・SWOT・企業財務分析
    Kewpie Corporation - Strategy, SWOT and Corporate Finance Report Summary Kewpie Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Syneos Health Inc：企業の戦略・SWOT・財務分析
    Syneos Health Inc - Strategy, SWOT and Corporate Finance Report Summary Syneos Health Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Servest Group Ltd：企業の戦略的SWOT分析
    Servest Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Par Pacific Holdings Inc (PARR)：石油・ガス：M&Aディール及び事業提携情報
    Summary Par Pacific Holdings Inc (Par Pacific), formerly known as Par Petroleum Corporation, manages, owns and maintains interests in energy and infrastructure related businesses. It has operations across the value chain from natural gas production to distribution and transportation. The company con …
  • Anthem, Inc.：企業のM&A・事業提携・投資動向
    Anthem, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Anthem, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Endonovo Therapeutics Inc (ENDV)：医療機器：M&Aディール及び事業提携情報
    Summary Endonovo Therapeutics Inc (Endonovo Therapeutics) is a commercial stage development company that offers non-invasive medical devices and equipment. The company’s products include Electroceutical Therapy a FDA-Cleared for the palliative treatment of pain and post-surgical edema and CE Marked …
  • Bangkok Bank Public Co Ltd：戦略・SWOT・企業財務分析
    Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Bangkok Bank Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Foundation for Innovative New Diagnostics-医療機器分野：企業M&A・提携分析
    Summary Foundation for Innovative New Diagnostics (FIND) is a non-profit organization that offers diagnostic tests. The organization develops and implements new diagnostic technologies for the development of diagnostic tests. Its services include diagnostic technologies development, quality-assured …
  • B&G Foods, Inc.：企業のM&A・事業提携・投資動向
    B&G Foods, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's B&G Foods, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Husky Energy Inc：企業の戦略・SWOT・財務分析
    Husky Energy Inc - Strategy, SWOT and Corporate Finance Report Summary Husky Energy Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Tokyo Gas Co Ltd (9531)：電力：M&Aディール及び事業提携情報
    Summary Tokyo Gas Co Ltd (Tokyo Gas) is a gas utility that produces, supplies and markets liquefied natural gas (LNG). It also produces, supplies and sells electricity. Tokyo Gas also has overseas upstream, midstream and downstream businesses. It provides engineering solutions, gas appliances and ga …
  • Morrison & Foerster LLP：企業の戦略的SWOT分析
    Morrison & Foerster LLP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Hankyu Hanshin Holdings, Inc.：企業の戦略・SWOT・財務情報
    Hankyu Hanshin Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Hankyu Hanshin Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆